Algorithms using genome-wide association studies for prediction of effectiveness of biologics in rheumatoid arthritis

Purpose: Two anti-TNF biologics, infliximab and etanercept, are extremely useful for inflammatory diseases such as rheumatoid arthritis (RA). However, approximately 20 to 30% of RA have been described as non-responders. Here, we analyzed the statistical relationships of whole genome single nucleotide polymorphisms (SNPs) with remission or low disease activity (LDA) among RA and developed algorithms using SNPs to predict effectiveness of these biologics.